SuperworthBridgeBio Oncology Therapeutics market cap BBOT
Share price times shares outstanding: what the whole company sells for, since 2024.
- Today, Oct 23, 2026
- $213.3M
- Highest close in our data
- $1.1B
- Dec 2025
BridgeBio Oncology Therapeutics is worth $213.3M at the close on Oct 23, 2026, at $2.66 a share.
That is down 17% over the last year.
Its highest close in our data was $1.1B in Dec 2025.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $213.3M | $213.3M | $1.1B | −78% |
| 2025 | $986.3M | $207.8M | $1.1B | +291% |
| 2024 | $252M | $234.6M | $253.9M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest BridgeBio Oncology Therapeutics' size, closest first, today.
| Company | Market cap |
|---|---|
| BBOTBridgeBio Oncology Therapeutics | $213.3M |
| NATRNatures Sunshine Products | $213.8M |
| ARVNArvinas | $477.3M |
| PBYIPuma Biotechnology | $568.9M |
| IRWDIronwood Pharmaceuticals | $571.7M |
| ZVRAZevra Therapeutics | $582.6M |
| CRMDCorMedix | $611.9M |
| LFVNLifevantage | $73.4M |
| SPROSpero Therapeutics | $64.6M |
| COLLCollegium Pharmaceutical | $747.5M |
| ABUSArbutus Biopharma | $831M |
| Peer median | $570.3M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on BridgeBio Oncology Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.